Tern Plc confirms no banking relationship with Silicon Valley Bank

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, provides the following statement regarding Silicon Valley Bank and Silicon Valley Bank UK Limited.

Tern confirms that the Company has no banking relationship, or other financing arrangements, with SVB.

While Tern Plc continues to monitor the SVB situation and its effect on Tern’s portfolio companies, the Directors of Tern do not currently believe that any of the portfolio companies’ exposure to SVB will have a significant impact on the net asset value of Tern.

Further announcements will be made, as necessary and appropriate, in due course.

Share on:

Written by: Jacob Brown

Find more news, interviews, share price & company profile here for:
Tern Plc

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

September 8, 2026

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

September 7, 2026

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

September 2, 2026

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

September 1, 2026

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

August 28, 2026

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.